VECIMA-NETWORKS-INC.
13.5.2024 13:31:28 CEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM), today announced its successful collaboration with Youcast in bringing the power of its MediaScale Open CDN™ technology to telecommunications and content providers in Brazil.
As the Youcast TV platform continues to grow, the company is poised to revolutionize content distribution in its region. In its strategic vision, Youcast sought a partner who could enhance its content delivery infrastructure and extend its capabilities to serve a broader content provider base.
Vecima, recognizing the unique opportunity to make a substantial impact on content distribution in South America, presented its MediaScale Open CDN™ solution to Youcast and was awarded the contract. Vecima’s MediaScale Open CDN is an implementation of the Streaming Video Technology Alliance’s Open Caching specifications. Open Caching is a technology specifically created to provide Content Providers with access to a Service Provider’s caching infrastructure, deep in the network, through a common set of configuration APIs.
MediaScale Open CDN allows service providers to monetize the terabytes of internet traffic delivered free of charge today and prepare their networks for the petabytes of content yet to come as streaming video consumption continues to rise. Subscribers get an improved viewing experience, without the headaches associated with congested networks that lead to rebuffering and poor video quality.
The collaboration between Vecima and Youcast represents a significant step toward establishing a highly efficient, cost-effective, and regionally-tailored content distribution network. With 80 points of presence in Brazil, Youcast can scale its content delivery with confidence.
"Our vision aligns perfectly with Vecima's commitment to powering content distribution through innovative solutions," said Raul Faller, CEO of Youcast. "By deploying Vecima’s Open CDN, we are not only enhancing Youcast’s capabilities but also introducing a transformative approach to content delivery in South America."
“Unlike conventional CDN models that often require separate infrastructure, Vecima’s MediaScale offering enables providers to get started with the infrastructure they already have in place,” said Kyle Goodwin, Senior Vice President and General Manager, Content Delivery & Storage business. “This approach reduces short-term implementation costs while providing long-term scalability and flexibility.”
For more information about Vecima's MediaScale solutions, vecima.com/video-streaming.
About Youcast
Youcast is a premier system integrator specializing in video platforms, renowned for its unmatched flexibility in offering diverse commercial models and technical solutions. In addition to our expertise in video platform integration, Youcast delivers comprehensive monitoring and security services based on cutting-edge cloud technology. With a relentless focus on innovation and reliability, Youcast empowers businesses to leverage the full potential of video content while maintaining the highest standards of security and compliance. To explore our comprehensive suite of services and harness the power of video with confidence, please visit Youcast.tv.br.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive. Learn more at vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513565937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom